BispecificsThatClick
Financiado
Combinatorial Antibody Synthesis for the Discovery of New Anti Tumour Immunomodu...
Cancer represents one of the major challenges for modern medicine as we still lack tools to selectively target malignant over healthy tissues. The main issues with state of the art anti-cancer treatments lie on their inefficiency...
Cancer represents one of the major challenges for modern medicine as we still lack tools to selectively target malignant over healthy tissues. The main issues with state of the art anti-cancer treatments lie on their inefficiency and their associated side-effects. Improving this treatments has focused a lot of attention of the scientific community and has led to the development of new strategies. Harnessing our own immune system to fight malignant cells is one of the strategies with promising potential to improve cancer treatments, although challenges still remain. An emerging therapeutic modality to trigger our immune system against carcinogenic tissues are bispecific antibodies (bsAbs). bsAbs are the combination of two antigen binding specificities on a common scaffold. The potential of these constructs to bind to two antigens can be used to simultaneously target cancer cells and the immune cell which will effectively kill it. The problem of bsAbs is their slow and tedious production process, which is responsible for their linear development. Herein we propose a methodology to speed up and improve the efficiency of their production. Our approach will consist in using novel site-specific bioorthogonal ligation reactions to tag monoclonal antibodies (mAbs) with linkers that will serve as substrates for an inverse electron demand Diels Alder condensation. By condensation of different combinations of tagged mAbs a library of bsAbs will be assembled. The immunondulatory properties of the bsAbs will be tested in high throughput using a high content imaging platform. We will be able to select potential bsAbs for anticancer treatment from our extense library which will study in more depth using classic immunology methods to determine their mode of action and their anti tumour efficacy. The acceleration of both the synthesis and identification of relevant bsAbs for anticancer treatments would significantly increase the presence and value of this technology.
ver más
Duración del proyecto: 25 meses
Fecha Inicio: 2019-04-09
Fecha Fin: 2021-06-02
Fecha Fin: 2021-06-02
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2021-06-02
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
MSCA-IF-2018:
Individual Fellowships
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
213K€
Líder del proyecto
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
283.28K€ |
Participante